On a DART-filed basis, annual revenue went from KRW 130 million in 2022 to KRW 267 million in 2023 (up 105.6% year on year), KRW 590 million in 2024 (up 120.9%) and KRW 1.17 billion in 2025 (up 98.5%).
Revenue has grown for three consecutive years from 2023 to 2025, and 2025 is the largest year of the 2022 to 2025 period.
Operating loss was KRW 16.2 billion in 2022, KRW 16.8 billion in 2023 (loss widened), KRW 12.3 billion in 2024 and KRW 6.44 billion in 2025 (loss narrowed), so the company has been loss-making for four consecutive years.
Operating margin moved from -12,425.1% in 2022 to -6,289.1% in 2023, -2,088.2% in 2024 and -549.6% in 2025, but with revenue this small the ratio is highly sensitive to the revenue base.
Net loss attributable to controlling shareholders was KRW 15.9 billion in 2022, KRW 15.2 billion in 2023, KRW 12.2 billion in 2024 and KRW 7.78 billion in 2025, a loss in each of the four years with the loss narrowing in 2024 and 2025.
Net loss including non-controlling interests is reported at the same amounts in each year, so the two figures match in this period. Operating cash outflow fell from KRW 11.3 billion in 2022 and KRW 14.2 billion in 2023 to KRW 9.71 billion in 2024 and KRW 5.92 billion in 2025.
Quarterly revenue was KRW 322 million in the third quarter of 2025, KRW 304 million in the fourth quarter (down 5.6% from the prior quarter), KRW 370 million in the first quarter of 2026 (up 21.8%), KRW 408 million in the second quarter (up 10.2%) and KRW 402 million in the third quarter of 2026 (down 1.5% from the prior quarter but up 24.8% year on year).
Operating loss widened from KRW 1.51 billion in the third quarter of 2025 to KRW 2.3 billion in the fourth quarter, then narrowed to KRW 1.01 billion, KRW 1.05 billion and KRW 582 million over the next three quarters, and the company has reported operating losses in five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.
Net loss attributable to controlling shareholders in the third quarter of 2026 was KRW 928 million, the smallest of the five quarters, and the four quarters from the fourth quarter of 2025 to the third quarter of 2026 total KRW 5.42 billion.
The company attributed part of the narrowing to higher royalty revenue and lower costs after the domestic MSA Phase 2 trial was halted.